BABHY-CART · Self-Healing Hydrogels for Material-Assisted Cell therapy in Osteoarthritis
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2020-12-31 → 2022-12-30
- Финансиране от ЕС
- 196 708 €
- Участници
- 2
- Схема
- MSCA-IF
Линиите свързват координатора с партньорите.
Накратко на български
Хидрогели на основата на хиалуронова киселина се разработват за инжектиране в ставите, за да подпомогнат действието на стволови клетки. Това е важно, защото остеоартритът е болезнено заболяване, което разрушава хрущялите и води до инвалидност при милиони хора.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
Self-Healing Hydrogels for Material-Assisted Cell therapy in Osteoarthritis
Peripheral joint osteoarthritis (OA) is an incurable and painful disease. As the most common rheumatic disease, it affects approximately 65 % of the population over 65. OA results primarily in the inflammation and destruction of the cartilaginous tissue, and can further expand to all structures of the joint, including bone and synovial membrane. Treatment normally involves palliative measures to reduce pain and swelling, and total joint replacement is often inevitable at a later stage of the disease. Over 70 million Europeans are currently affected by OA – a number that is set to increase with aging population and prevalence of obesity. OA is expected to become the 4th leading cause of world-wide disability by 2020-2030, with an estimated burden to society as high as 817 billion euros/year for total costs in Europe. To date, no clinically-efficient therapy exists to treat this socioeconomically debilitating disease. In this context, innovative regenerative therapies for joints are a pressing medical challenge. The overall objective of the BABHY-CART project is to develop a novel hydrogel-assisted cell therapy for osteoarthritis treatment. To succeed, we envisioned to design an injectable hyaluronic acid (HA)-based hydrogel with long-lasting viscoelastic properties, mechanically suited for intra-articular injections, and that would enhance the immunomodulatory properties of encapsulated stem cells.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Osteoarthritis (OA) is an incurable and painful disease. Over 70 million Europeans are currently affected by OA – a number that is set to increase with aging population and prevalence of obesity. To date, no clinically-efficient therapy exists to treat this socioeconomically debilitating disease. In this context, innovative regenerative therapies for joints are a pressing medical challenge.Intraarticular mesenchymal stromal cell (MSC) injections hold the great promise of stopping and reversing age-associated inflammation and degeneration of joints by providing the necessary trophic factors to mitigate immune responses. However, translational progress using conventional cell delivery (saline) has been seriously hampered by the limited control over cell survival, location and fate in damaged joints. It is now common knowledge that cell microenvironment plays a crucial role in the success of cell transplantation; and appropriate synthetic matrix design is key to success.To address challenges in intraarticular MSC-based immunomodulation strategies, we have envisioned an original hydrogel-assisted cell therapy. In this strategy, an injectable hyaluronic acid (HA)-based hydrogel with long-lasting viscoelastic properties will allow MSC encapsulation and cytoprotection, ensuring the production of anti-OA soluble factors in vivo. To best mimic synovial environment and support MSCs in vivo, we will synthesize a novel boronic acid-based, self-healing HA hydrogel with unique properties of injectability, stability and fast relaxation under mechanical load.After carefully characterizing the physicochemical properties of this new class of biomaterials, we will investigate the effects of cell encapsulation on adipose stromal cell (ASC) survival, morphology and factor secretion. Then, the preclinical efficacy of intraarticular injections of cell-loaded, self-healing hydrogels will be confirmed in two complementary OA mice models.
Оригинален текст от CORDIS (на английски).
Участници
Връзки
Данни: CORDIS, © Европейски съюз